Dr. Clay Siegall founded Seattle Genetics in 1998. He is the current president, CEO and a member of the Board of Directors of the company. The company has been researching and developing a variety of clinical and pre-clinical products aimed at treating some cancer and other autoimmune illnesses. The successes that the company has achieved so far include the creation of the anti body conjugate, ADCETRIS, which got approval from the FDA a few years ago.
The man behind the success of the clinical trials company has been Clay Siegall. He has assisted the company in raising more than $330 million through both public and private funding. In 2001, he agreed to have the company listed in an IPO at NASDAQ. Their shares have been trading under the name of SGEN. Other agreements that have helped raise funds for the group include the worldwide cooperation they entered into with Genentech for SGN-40. The product was valued at $860 million. Others include Curagen, Bayer, MedImmune, and Progenics, all who have brought in a total of $65 million in the past decade.
There are some institutions that Clay Siegall had worked with before founding Seattle Genetics. These include Bristol Myers Squibb Pharmaceutical and the National Cancer Institute. He branched off to start his own company because he felt that he could make as much impact as he dreamed if he was working in his terms. Clay has a B.S in Zoology from the University of Maryland, and a Ph.D. in genetics from the George Washington University.
When asked what the company was planning to do next, he explained that unlike the other companies who sell off to Big Pharma after making their breakthrough, he was planning to stay and expand the reach of Seattle Genetics. He added that they have been with the company even in the past when things were complicated and that their vision was to become a global leader in offering workable treatments for cancer and related indications. He added that they had no intentions of selling off anytime soon.